As of August 2014, Dr. Mumper is no longer taking students or post-doctoral fellows.
Research interests have focused primarily in five areas including; 1) nanotemplate engineering of nano-based detection devices and cell-specific nanoparticles for tumor and dendritic cell targeting and vaccines, 2) biocompatibility, hemocompatibility, and toxicology of nanoparticles and nanomaterials, 3) antibody-drug conjugates, 4) mucoadhesive gels, thin-films, and intravaginal rings for (trans)mucosal delivery of drugs, vaccines, and microbicides, and 5) anticancer and anti-inflammatory properties of berries and berry extracts.
Dr. Russell Mumper joined the University of Georgia as its vice provost for academic affairs in August 2014 following a national search. He was previously vice dean and John A. McNeill Distinguished Professor at the University of North Carolina-Chapel Hill Eshelman School of Pharmacy. He has received nearly $30 million in research grants and contracts and has published more than 300 peer-reviewed scientific manuscripts and abstracts in areas such as nanotechnology, drug delivery and plant-based anti-cancer and anti-inflammatory compounds. He is a named inventor on 48 patents or patent families, many of which have been licensed to companies, and has co-founded five companies as a faculty member. In addition, he has started and led or co-led several multidisciplinary research, development and manufacturing centers.
Mumper began his academic career in 1999 at the University of Kentucky College of Pharmacy, after spending nearly a decade working in the pharmaceutical and biotechnology industries. He has received several research and education honors throughout his career. In 2007, the University of Kentucky Alumni Association recognized him as one of six “Great Teachers” at UK, the oldest continuously given award for teaching at the institution. In 2013, he received the Distinguished Teaching Award for Post-Baccalaureate Instruction, a campus-wide award at UNC.
L Peng, L Feng, H Yuan, SR Benhabbour and RJ Mumper. Development of a Novel Orthotopic Non-small Cell Lung Cancer Model and Therapeutic Benefit of 2’-(2-bromohexadecanoyl)-Docetaxel Conjugate Nanoparticles. Nanomedicine: Nanotechnology, Biology and Medicine. (2014) 10(7):1497-1506.
JE McLaughlin, MT Roth, D Glatt-Dowd, N Gharkholonarehe, C Davidson, L Griffin, D Esserman and RJ Mumper. The Flipped Classroom: A Course Redesign to Foster Learning and Engagement in a Health Professions School. Academic Medicine. (2014) 89(2):236-243.
P Ma, SR Benhabbour, L Feng and RJ Mumper. 2′-Behenoyl-Paclitaxel Conjugate Containing Lipid Nanoparticles for the Treatment of Metastatic Breast Cancer. Cancer Letters. (2013) 334(2):253-262.
D Liu, T Kobayashi, S Russo, F Li, SE Plevy, TM Gambling, JL Carson and RJ Mumper. In-Vitro and In-Vivo Evaluation of a Water-in-Oil Microemulsion System for Enhanced Peptide Intestinal Delivery. AAPS Journal. (2013) 15(1):288-298.
SR Benhabbour, JC Luft, D Kim, A Jain, S Wadhwa, MC Parrott, R Liu, J DeSimone and RJ Mumper. In- Vitro and In-Vivo Assessment of Targeting Lipid-based Nanoparticles to the Epidermal Growth Factor-Receptor (EGFR) Using a Novel Heptameric ZEGFR Domain. Journal of Controlled Release. (2012) 158(1):63-71.
X Dong, CA Mattingly, M Tseng, M Cho, Y Liu, VR Adams and RJ Mumper. Doxorubicin and Paclitaxel-loaded Lipid-based Nanoparticles Overcome Multi-Drug Resistance By Inhibiting P-gp via ATP Depletion. Cancer Research. (2009) 69(9):3918-3926.
See more publications for Dr. Mumper at Google Scholar.